ClinicalTrials.gg
RecruitingNCT06921902PREMAPUpdated Apr 9, 2026

Glycemic Metrics and Patterns in People With and Without Prediabetes

An observational study in Pre Diabetes, sponsored by Abbott Diabetes Care. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Abbott Diabetes Care (part of Abbott) · Observational

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 350 studies in Glucose Intolerance with a site in United States — 44 open to participants now, 65 under way, none of them phase 3. Glucose Intolerance · United States.

Planned enrollment
Largest of 40
2,000 · median 107
Started
2025
with 15 others
Observational
41 of 350
7 open now
Primary completion
2026-12
later than 25 of 64 live
Registered
328th of 350
by date

Among the 350 studies in Glucose Intolerance with a site in United States, this one has the largest planned enrollment of the 40 observational ones that give a count, is one of 16 that started in 2025, is one of 41 observational ones, reaches primary completion later than 25 of the 64 other live ones, and was the 328th registered.

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

Browse Glucose Intolerance studies →

Open to participants now

44 of the 350 studies in Glucose Intolerance with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Glucose Intolerance studies recruiting now, 14 (20%) set no upper age limit and 51 (73%) stop at 75 or younger; 10 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 350 studies in Glucose Intolerance with a site in United States, or all of them as a file.
02

Study summary

The FreeStyle Libre 3 Continuous Glucose Monitoring (FSL3) System is used to characterize the glycemic profiles of people with and without a prediabetes diagnosis.

Read the detailed description

This is a non-pivotal, non-randomized, multi-center, prospective, non-significant risk to evaluate the glycemic profiles of people with and without a prediabetes diagnosis using continuous glucose monitoring. Up to 2000 subjects will be enrolled in up to 20 sites. Approximately 50% of evaluable subjects will have a prediabetes diagnosis.

03

Conditions studied

  • Pre Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects will be stratified into groups, including male and female sex, race, age and Body Mass Index. Approximately 25 evaluable subjects will be enrolled into each group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 18 years of age.
  • Subject must be willing and able to provide written signed and dated .

Exclusion criteria

Exclusion Criteria:

  • Subject has a diagnosis of type 1 diabetes, type 2 diabetes, or gestational diabetes.
  • Subject is known to be currently practicing a low-carbohydrate or ketogenic diet at the time of enrollment.
  • Subject is known to be pregnant at the time of enrollment.
  • Subject has known allergy to medical grade adhesive, isopropyl alcohol and/or ethyl alcohol used to disinfect skin.
  • Subject is currently on any form of treatment indicated for the treatment of diabetes.
  • Subject is currently on any form of medication indicated for weight loss.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Interventions

  • DeviceFreeStyle Libre 3

    Abbott Sensor Based Glucose Monitoring System (FreeStyle Libre 3 System)

    Also known as: FreeStyle Libre 3 Monitoring System

06

What researchers measure

Primary outcomes

  1. Characterize the glycemic profiles of people with and without a prediabetes diagnosis.

    This is a data collection study.

    Time frame: up to 50 days

07

Study locations

1 of 1 sites recruiting
  • Diabetes and Obesity Care
    Bend, Oregon 97702, United States
    Recruiting
    • Eden Miller, D.O. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 33 observational studies under Glucose Intolerance, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 186. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 10, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06921902
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Feb 28, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 9, 2026

Study contacts

MOHAMED NADA, PhD
Contact
adc.clinical@abbott.com
5107495416
Shridhara Karinka, PhD
study chair · Abbott Diabetes Care

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion